Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
09 déc. 2023 20h30 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
27 nov. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
15 nov. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics announces participation in upcoming conferences
06 nov. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces participation in upcoming conferences
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
02 nov. 2023 09h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
02 nov. 2023 07h11 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
17 oct. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
11 oct. 2023 08h07 HE
|
Autolus Therapeutics plc
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
11 oct. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
05 sept. 2023 07h00 HE
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...